Abstract
COLAL-PRED (prednisolone sodium metasulfobenzoate), which is targeted to the colon by COLAL colonic drug delivery technology, is being developed by Alizyme for the potential treatment of inflammatory bowel disease. Alizyme expect to initiate a phase III trial in 2005.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1192-1197 |
| Number of pages | 6 |
| Journal | Current Opinion in Investigational Drugs |
| Volume | 5 |
| Issue number | 11 |
| State | Published - Nov 1 2004 |
ASJC Scopus subject areas
- Pharmacology